Filed with ASX · · 11 pages · English
The report indicates a strong start to the financial year, with significant growth in cash receipts and positive operating cash flow. The company reaffirms its revenue guidance for the financial year, projecting substantial growth compared to the previous year. BLS continues to expand its manufacturing capabilities both domestically and internationally, particularly in Germany and the United Kingdom.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Suite 506, Level 5 50 Clarence Street, Sydney NSW 2000, Australia hello@breathelifesciences.com +61 2 9078 8180 BLS Pharmaceuticals Ltd | ASX:BLS | www.blspharma.com 1 15 October 2026 Quarterly Activities Report Period Ending 30 September 2026 Record $26.7 million Q1 revenue provides...
BLS Pharmaceuticals Limited on 6ix
Follow BLS Pharmaceuticals into a list and get an email when it puts out news.
Follow BLS Pharmaceuticals